From the Office of the Governor

State of North CarolinaOffice of the Governor20301 Mail Service Center • Raleigh, NC 27699-0301Michael F. EasleyGovernorFebruary 26, 2007Dear Readers:Almost 25 years ago, North Carolina led the way to build a new economic engine called biotechnology. We created the world's first government-sponsored biotechnology center and began making systematic, long-term State investments in biotechnology infrastructure.Today North Carolina is the nation's third largest biotech state, with more than 350

Written byMichael F. Easley
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

State of North Carolina
Office of the Governor
20301 Mail Service Center • Raleigh, NC 27699-0301

Michael F. Easley
Governor
February 26, 2007

Dear Readers:

Almost 25 years ago, North Carolina led the way to build a new economic engine called biotechnology. We created the world's first government-sponsored biotechnology center and began making systematic, long-term State investments in biotechnology infrastructure.

Today North Carolina is the nation's third largest biotech state, with more than 350 bioscience companies employing 48,000 people and thousands more working in bioscience research labs at our world-class public and private universities.

We've come a long way since 1984, but we aspire to do even more. We're executing a statewide strategic plan, New Jobs Across North Carolina, aimed at giving us 125,000 bioscience jobs by 2023. Our strategy for developing biotechnology across our state through regional offices of the North Carolina Biotechnology Center is unique among the states.

This special publication of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies